Anand Bagaria, senior research analyst, Finquest explains to CNBC-TV18 that pharma major Wockhardt has posted a strong run in terms of a stock performance as well as fundamentals and gained over 250% from the start of the year.
first published: Aug 7, 2012 03:22 pm
A collection of the most-viewed Moneycontrol videos.
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live
Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
